{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:37Z","timestamp":1787582377979,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,16]]},"DOI":"10.7759\/cureus.43603","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T03:59:31Z","timestamp":1692244771000},"source":"Crossref","is-referenced-by-count":1,"title":["Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis"],"prefix":"10.7759","author":[{"given":"Himabindu","family":"Sreenivasulu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer kumar","family":"Muppalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravya","family":"Vuppalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shokrolahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeksha","family":"Reddy Pulliahgaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.24875\/BMHIM.20000372","article-title":"Cystic fibrosis: current concepts","volume":"78","author":"L\u00f3pez-Valdez JA","year":"2021","unstructured":"L\u00f3pez-Valdez JA, Aguilar-Alonso LA, G\u00e1ndara-Quezada V, Ruiz-Rico GE, \u00c1vila-Soledad JM, Reyes AA, Pedroza-Jim\u00e9nez FD. Cystic fibrosis: current concepts. Bol Med Hosp Infant Mex. 2021, 78:584-96. 10.24875\/BMHIM.20000372","journal-title":"Bol Med Hosp Infant Mex"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet V","year":"2020","unstructured":"Scotet V, L'Hostis C, F\u00e9rec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes. 2020, 11:589. 10.3390\/genes11060589","journal-title":"Genes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios NL","year":"2020","unstructured":"Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care. 2020, 65:233-51. 10.4187\/respcare.06697","journal-title":"Respir Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall MA","year":"2014","unstructured":"Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014, 44:1042-54. 10.1183\/09031936.00228013","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2016.04.004","article-title":"Cystic fibrosis diagnosis and newborn screening","volume":"63","author":"Rosenfeld M","year":"2016","unstructured":"Rosenfeld M, Sontag MK, Ren CL. Cystic fibrosis diagnosis and newborn screening. Pediatr Clin North Am. 2016, 63:599-615. 10.1016\/j.pcl.2016.04.004","journal-title":"Pediatr Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2017.04.010","article-title":"The diagnosis of cystic fibrosis","volume":"46","author":"De Boeck K","year":"2017","unstructured":"De Boeck K, Vermeulen F, Dupont L. The diagnosis of cystic fibrosis. Presse M\u00e9d. 2017, 46:e97-e108. 10.1016\/j.lpm.2017.04.010","journal-title":"Presse M\u00e9d"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.01.004","article-title":"European best practice guidelines for cystic fibrosis neonatal screening","volume":"8","author":"Castellani C","year":"2009","unstructured":"Castellani C, Southern KW, Brownlee K, et al.. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009, 8:153-73. 10.1016\/j.jcf.2009.01.004","journal-title":"J Cyst Fibros"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37562016000000076","article-title":"Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of S\u00e3o Paulo, Brazil","volume":"43","author":"Servidoni MF","year":"2017","unstructured":"Servidoni MF, Gomez CC, Marson FA, Toro AA, Ribeiro M\u00c2GO, Ribeiro JD, Ribeiro AF. Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of S\u00e3o Paulo, Brazil. J Bras Pneumol. 2017, 43:121-8. 10.1590\/S1806-37562016000000076","journal-title":"J Bras Pneumol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell PM","year":"2008","unstructured":"Farrell PM, Rosenstein BJ, White TB, et al.. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008, 153:S4-S14. 10.1016\/j.jpeds.2008.05.005","journal-title":"J Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.02.002","article-title":"Genetic screening for cystic fibrosis: an overview of the science and the economics","volume":"6","author":"Brice P","year":"2007","unstructured":"Brice P, Jarrett J, Mugford M. Genetic screening for cystic fibrosis: an overview of the science and the economics. J Cyst Fibros. 2007, 6:255-61. 10.1016\/j.jcf.2007.02.002","journal-title":"J Cyst Fibros"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg M","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021, 397:2195-211. 10.1016\/s0140-6736(20)32542-3","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.10.003","article-title":"CFTR: folding, misfolding and correcting the \u0394F508 conformational defect","volume":"18","author":"Lukacs GL","year":"2012","unstructured":"Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the \u0394F508 conformational defect. Trends Mol Med. 2012, 18:0-91. 10.1016\/j.molmed.2011.10.003","journal-title":"Trends Mol Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng SH","year":"1990","unstructured":"Cheng SH, Gregory RJ, Marshall J. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990, 63:827-34. 10.1016\/0092-8674(90)90148-8","journal-title":"Cell"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.13.7261","article-title":"Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway","volume":"271","author":"Qu BH","year":"1996","unstructured":"Qu BH, Thomas PJ. Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J Biol Chem. 1996, 271:7261-4. 10.1074\/jbc.271.13.7261","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-1993(11)60009-x","article-title":"New clinical diagnostic procedures for cystic fibrosis in Europe","volume":"10","author":"De Boeck K","year":"2011","unstructured":"De Boeck K, Derichs N, Fajac I, et al.. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros. 2011, 10:S53-S66.. 10.1016\/s1569-1993(11)60009-x","journal-title":"J Cyst Fibros"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201454","article-title":"Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?","volume":"67","author":"Ooi CY","year":"2012","unstructured":"Ooi CY, Dupuis A, Ellis L, et al.. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?. Thorax. 2012, 67:618-24. 10.1136\/thoraxjnl-2011-201454","journal-title":"Thorax"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski M","year":"2006","unstructured":"Wilschanski M, Dupuis A, Ellis L, et al.. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med. 2006, 174:787-94. 10.1164\/rccm.200509-1377OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic fibrosis related diabetes: nutrition and growth considerations","volume":"18","author":"Kaminski BA","year":"2019","unstructured":"Kaminski BA, Goldsweig BK, Sidhaye A, Blackman SM, Schindler T, Moran A. Cystic fibrosis related diabetes: nutrition and growth considerations. J Cyst Fibros. 2019, 18:S32-7. 10.1016\/j.jcf.2019.08.011","journal-title":"J Cyst Fibros"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040853","article-title":"Nutrition in cystic fibrosis - some notes on the fat recommendations","volume":"14","author":"Strandvik B","year":"2022","unstructured":"Strandvik B. Nutrition in cystic fibrosis - some notes on the fat recommendations. Nutrients. 2022, 14:853. 10.3390\/nu14040853","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.007","article-title":"Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand","volume":"19","author":"van der Haak N","year":"2020","unstructured":"van der Haak N, King SJ, Crowder T, Kench A, Painter C, Saxby N. Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand. J Cyst Fibros. 2020, 19:16-25. 10.1016\/j.jcf.2019.05.007","journal-title":"J Cyst Fibros"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity","volume":"14","author":"Bailey J","year":"2022","unstructured":"Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients. 2022, 14:1216. 10.3390\/nu14061216","journal-title":"Nutrients"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006842.pub5","article-title":"Oscillating devices for airway clearance in people with cystic fibrosis","volume":"4","author":"Morrison L","year":"2020","unstructured":"Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. 2020, 4:CD006842. 10.1002\/14651858.CD006842.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.01.013","article-title":"Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: a randomised controlled trial","volume":"148","author":"Zeren M","year":"2019","unstructured":"Zeren M, Cakir E, Gurses HN. Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: a randomised controlled trial. Respir Med. 2019, 148:24-30. 10.1016\/j.rmed.2019.01.013","journal-title":"Respir Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003147.pub5","article-title":"Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis","volume":"2019","author":"McIlwaine M","year":"2019","unstructured":"McIlwaine M, Button B, Nevitt SJ. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. 2019, 2019:10.1002\/14651858.CD003147.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013285.pub2","article-title":"Exercise versus airway clearance techniques for people with cystic fibrosis","volume":"6","author":"Heinz KD","year":"2022","unstructured":"Heinz KD, Walsh A, Southern KW, Johnstone Z, Regan KH. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database Syst Rev. 2022, 6:10.1002\/14651858.CD013285.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.01w.003","article-title":"Bacterial contamination of cystic fibrosis clinics","volume":"8","author":"Zuckerman JB","year":"2009","unstructured":"Zuckerman JB, Zuaro DE, Prato BS, et al.. Bacterial contamination of cystic fibrosis clinics. J Cyst Fibros. 2009, 8:186-92. 10.1016\/j.jcf.2009.01w.003","journal-title":"J Cyst Fibros"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201707-1457OC","article-title":"Face masks and cough etiquette reduce the cough aerosol concentration of Pseudomonas aeruginosa in people with cystic fibrosis","volume":"197","author":"Wood ME","year":"2018","unstructured":"Wood ME, Stockwell RE, Johnson GR, et al.. Face masks and cough etiquette reduce the cough aerosol concentration of Pseudomonas aeruginosa in people with cystic fibrosis. Am J Respir Crit Care Med. 2018, 197:348-55. 10.1164\/rccm.201707-1457OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1595594","article-title":"Infection prevention and control in cystic fibrosis: a systematic review of interventions","volume":"13","author":"Rowbotham NJ","year":"2019","unstructured":"Rowbotham NJ, Palser SC, Smith SJ, Smyth AR. Infection prevention and control in cystic fibrosis: a systematic review of interventions. Expert Rev Respir Med. 2019, 13:425-34. 10.1080\/17476348.2019.1595594","journal-title":"Expert Rev Respir Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35","author":"Saiman L","year":"2014","unstructured":"Saiman L, Siegel JD, LiPuma JJ, et al.. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014, 35:S1-S67. 10.1086\/676882","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201805-0823LE","article-title":"Face masks reduce the release of Pseudomonas aeruginosa cough aerosols when worn for clinically relevant periods","volume":"198","author":"Stockwell RE","year":"2018","unstructured":"Stockwell RE, Wood ME, He C, et al.. Face masks reduce the release of Pseudomonas aeruginosa cough aerosols when worn for clinically relevant periods. Am J Respir Crit Care Med. 2018, 198:1339-42. 10.1164\/rccm.201805-0823LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1877LE","article-title":"Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies","volume":"191","author":"Zuckerman JB","year":"2015","unstructured":"Zuckerman JB, Clock SA, Prato BS, et al.. Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies. Am J Respir Crit Care Med. 2015, 191:598-601. 10.1164\/rccm.201410-1877LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis839","article-title":"An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms","volume":"56","author":"Passaretti CL","year":"2013","unstructured":"Passaretti CL, Otter JA, Reich NG, et al.. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis. 2013, 56:27-35. 10.1093\/cid\/cis839","journal-title":"Clin Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1086\/670222","article-title":"Improving healthcare environmental cleaning and disinfection: current and evolving issues","volume":"34","author":"Carling PC","year":"2013","unstructured":"Carling PC, Huang SS. Improving healthcare environmental cleaning and disinfection: current and evolving issues. Infect Control Hosp Epidemiol. 2013, 34:507-13. 10.1086\/670222","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-6701(97)90195-x","article-title":"Low bacterial contamination of nebulizers in-home treatment of cystic fibrosis patients","volume":"36","author":"Jakobsson BM","year":"1997","unstructured":"Jakobsson BM, Onnered AB, Hjelte L, Nystr\u00f6m B. Low bacterial contamination of nebulizers in-home treatment of cystic fibrosis patients. J Hosp Infect. 1997, 36:201-7. 10.1016\/s0195-6701(97)90195-x","journal-title":"J Hosp Infect"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu PT","year":"2006","unstructured":"Liu PT, Stenger S, Li H, et al.. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006, 311:1770-3. 10.1126\/science.1123933","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2015.09.013","article-title":"Treatment of vitamin D deficiency in cystic fibrosis","volume":"164","author":"Chesdachai S","year":"2016","unstructured":"Chesdachai S, Tangpricha V. Treatment of vitamin D deficiency in cystic fibrosis. J Steroid Biochem Mol Biol. 2016, 164:36-9. 10.1016\/j.jsbmb.2015.09.013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000096","article-title":"Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis","volume":"21","author":"Siwamogsatham O","year":"2014","unstructured":"Siwamogsatham O, Alvarez JA, Tangpricha V. Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis. Curr Opin Endocrinol Diabetes Obes. 2014, 21:422-9. 10.1097\/MED.0000000000000096","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2016.259","article-title":"Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial","volume":"71","author":"Pincikova T","year":"2017","unstructured":"Pincikova T, Paquin-Proulx D, Sandberg JK, Flodstr\u00f6m-Tullberg M, Hjelte L. Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. Eur J Clin Nutr. 2017, 71:203-5. 10.1038\/ejcn.2016.259","journal-title":"Eur J Clin Nutr"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23161","article-title":"Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis","volume":"50","author":"Vanstone MB","year":"2015","unstructured":"Vanstone MB, Egan ME, Zhang JH, Carpenter TO. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2015, 50:441-6. 10.1002\/ppul.23161","journal-title":"Pediatr Pulmonol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201208-068OC","article-title":"Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis","volume":"11","author":"McCauley LA","year":"2014","unstructured":"McCauley LA, Thomas W, Laguna TA, Regelmann WE, Moran A, Polgreen LE. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2014, 11:198-204. 10.1513\/AnnalsATS.201208-068OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub3","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark P","year":"2009","unstructured":"Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009, 10.1002\/14651858.CD001506.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcp.0000245714.89632.b2","article-title":"Inhaled hypertonic saline as a therapy for cystic fibrosis","volume":"12","author":"Elkins MR","year":"2006","unstructured":"Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006, 12:445-52. 10.1097\/01.mcp.0000245714.89632.b2","journal-title":"Curr Opin Pulm Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/adc.70.2.84","article-title":"Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period","volume":"70","author":"Weaver LT","year":"1994","unstructured":"Weaver LT, Green MR, Nicholson K, et al.. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child. 1994, 70:84-9. 10.1136\/adc.70.2.84","journal-title":"Arch Dis Child"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius NH","year":"1991","unstructured":"Valerius NH, Koch C, H\u00f8iby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991, 338:725-6. 10.1016\/0140-6736(91)91446-2","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1099-0496(199909)28:3159","article-title":"Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)","volume":"28","author":"Frederiksen B","year":"1999","unstructured":"Frederiksen B, Koch C, H\u00f8iby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol. 1999, 28:3-159. 10.1002\/(sici)1099-0496(199909)28:3159","journal-title":"Pediatr Pulmonol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub5","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","volume":"9","author":"Rosenfeld M","year":"2020","unstructured":"Rosenfeld M, Rayner O, Smyth AR. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2020, 9:10.1002\/14651858.CD001912.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.120269","article-title":"Cystic fibrosis: a 2002 update","volume":"140","author":"Orenstein DM","year":"2002","unstructured":"Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr. 2002, 140:156-64. 10.1067\/mpd.2002.120269","journal-title":"J Pediatr"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1136\/adc.81.2.129","article-title":"The evolution of liver disease in cystic fibrosis","volume":"81","author":"Ling SC","year":"1999","unstructured":"Ling SC, Wilkinson JD, Hollman AS, McColl J, Evans TJ, Paton JY. The evolution of liver disease in cystic fibrosis. Arch Dis Child. 1999, 81:129-32. 10.1136\/adc.81.2.129","journal-title":"Arch Dis Child"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp031540","article-title":"Prevention of hepatitis A with the hepatitis A vaccine","volume":"350","author":"Craig AS","year":"2004","unstructured":"Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004, 350:476-81. 10.1056\/NEJMcp031540","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.10.003","article-title":"Immunisation in the current management of cystic fibrosis patients","volume":"4","author":"Malfroot A","year":"2005","unstructured":"Malfroot A, Adam G, Ciofu O, et al.. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros. 2005, 4:77-87. 10.1016\/j.jcf.2004.10.003","journal-title":"J Cyst Fibros"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3109\/00365549109024311","article-title":"Varicella-zoster infection in adults with cystic fibrosis: role of acyclovir","volume":"23","author":"Ong EL","year":"1991","unstructured":"Ong EL, Mulvenna P, Webb KA. Varicella-zoster infection in adults with cystic fibrosis: role of acyclovir. Scand J Infect Dis. 1991, 23:283-5. 10.3109\/00365549109024311","journal-title":"Scand J Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe020138","article-title":"Varicella vaccine - are two doses better than one?","volume":"347","author":"Gershon AA","year":"2002","unstructured":"Gershon AA. Varicella vaccine - are two doses better than one?. N Engl J Med. 2002, 347:1962-3. 10.1056\/NEJMe020138","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1981.tb05757.x","article-title":"Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa","volume":"70","author":"Petersen NT","year":"1981","unstructured":"Petersen NT, H\u00f8iby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981, 70:623-8. 10.1111\/j.1651-2227.1981.tb05757.x","journal-title":"Acta Paediatr Scand"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001273420401","article-title":"The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children","volume":"342","author":"Neuzil KM","year":"2000","unstructured":"Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000, 342:225-31. 10.1056\/NEJM200001273420401","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh MC","year":"2021","unstructured":"Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK. A new era for people with cystic fibrosis. Eur J Pediatr. 2021, 180:2731-9. 10.1007\/s00431-021-04168-y","journal-title":"Eur J Pediatr"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/nu14071341\u00a0","article-title":"Pancreatic enzyme replacement therapy in cystic fibrosis","volume":"14","author":"Freswick PN","year":"2022","unstructured":"Freswick PN, Reid EK, Mascarenhas MR. Pancreatic enzyme replacement therapy in cystic fibrosis. Nutrients. 2022, 14:1341. 10.3390\/nu14071341\u00a0","journal-title":"Nutrients"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss CH","year":"2019","unstructured":"Goss CH. Acute pulmonary exacerbations in cystic fibrosis. Semin Respir Crit Care Med. 2019, 40:792-803. 10.1055\/s-0039-1697975","journal-title":"Semin Respir Crit Care Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Hewer SC","year":"2020","unstructured":"Hewer SC, Smyth AR, Brown M, et al.. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med. 2020, 8:975-86. 10.1016\/S2213-2600(20)30331-3","journal-title":"Lancet Respir Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.10.005","article-title":"New concepts in antimicrobial resistance in cystic fibrosis respiratory infections","volume":"21","author":"Drevinek P","year":"2022","unstructured":"Drevinek P, Canton R, Johansen HK, Hoffman L, Coenye T, Burgel PR, Davies JC. New concepts in antimicrobial resistance in cystic fibrosis respiratory infections. J Cyst Fibros. 2022, 21:937-45. 10.1016\/j.jcf.2022.10.005","journal-title":"J Cyst Fibros"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16144","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher A","year":"2021","unstructured":"Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus. 2021, 13:e16144. 10.7759\/cureus.16144","journal-title":"Cureus"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard L","year":"2022","unstructured":"Regard L, Martin C, Burnet E, Da Silva J, Burgel PR. CFTR modulators in people with cystic fibrosis: real-world evidence in France. Cells. 2022, 11:1769. 10.3390\/cells11111769","journal-title":"Cells"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall MA","year":"2020","unstructured":"Mall MA. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. Eur Respir J. 2020, 56:2000946. 10.1183\/13993003.00946-2020","journal-title":"Eur Respir J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz139","article-title":"Advances in gene therapy for cystic fibrosis lung disease","volume":"28","author":"Yan Z","year":"2019","unstructured":"Yan Z, McCray PB Jr, Engelhardt JF. Advances in gene therapy for cystic fibrosis lung disease. Hum Mol Genet. 2019, 28:R88-R94. 10.1093\/hmg\/ddz139","journal-title":"Hum Mol Genet"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113903","article-title":"Gene therapy for cystic fibrosis: progress and challenges of genome editing","volume":"21","author":"Maule G","year":"2020","unstructured":"Maule G, Arosio D, Cereseto A. Gene therapy for cystic fibrosis: progress and challenges of genome editing. Int J Mol Sci. 2020, 21:3903. 10.3390\/ijms21113903","journal-title":"Int J Mol Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.137","article-title":"Treating cystic fibrosis with mRNA and CRISPR","volume":"31","author":"Da Silva Sanchez A","year":"2020","unstructured":"Da Silva Sanchez A, Paunovska K, Cristian A, Dahlman JE. Treating cystic fibrosis with mRNA and CRISPR. Hum Gene Ther. 2020, 31:940-55. 10.1089\/hum.2020.137","journal-title":"Hum Gene Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114858118","article-title":"Exon-skipping antisense oligonucleotides for cystic fibrosis therapy","volume":"119","author":"Kim YJ","year":"2022","unstructured":"Kim YJ, Sivetz N, Layne J, Voss DM, Yang L, Zhang Q, Krainer AR. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. Proc Natl Acad Sci. 2022, 119:e2114858118. 10.1073\/pnas.2114858118","journal-title":"Proc Natl Acad Sci"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.4187\/002013209790983197","article-title":"Lung transplantation in cystic fibrosis","volume":"54","author":"Rosenblatt RL","year":"2009","unstructured":"Rosenblatt RL. Lung transplantation in cystic fibrosis. Respir Care. 2009, 54:777-87. 10.4187\/002013209790983197","journal-title":"Respir Care"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos KJ","year":"2019","unstructured":"Ramos KJ, Smith PJ, McKone EF, et al.. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019, 18:321-33. 10.1016\/j.jcf.2019.03.002","journal-title":"J Cyst Fibros"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23916","article-title":"Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management","volume":"53","author":"Nicolais CJ","year":"2018","unstructured":"Nicolais CJ, Bernstein R, Riekert KA, Quittner AL. Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatr Pulmonol. 2018, 53:162-73. 10.1002\/ppul.23916","journal-title":"Pediatr Pulmonol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1097\/01.NURSE.0000279437.30155.1e","article-title":"What you need to know about cystic fibrosis","volume":"37","author":"Gardner J","year":"2007","unstructured":"Gardner J. What you need to know about cystic fibrosis. Nursing. 2007, 37:52-5. 10.1097\/01.NURSE.0000279437.30155.1e","journal-title":"Nursing"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.5604\/1232-1966.1108617","article-title":"Disease specific knowledge about cystic fibrosis, patient education and counselling in Poland","volume":"21","author":"Chomik S","year":"2014","unstructured":"Chomik S, Klincewicz B, Cichy W. Disease specific knowledge about cystic fibrosis, patient education and counselling in Poland. Ann Agric Environ Med. 2014, 21:420-4. 10.5604\/1232-1966.1108617","journal-title":"Ann Agric Environ Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2018.06.004","article-title":"Cystic fibrosis-related education: are we meeting patient and caregiver expectations?","volume":"101","author":"Lonabaugh KP","year":"2018","unstructured":"Lonabaugh KP, O'Neal KS, McIntosh H, Condren M. Cystic fibrosis-related education: are we meeting patient and caregiver expectations?. Patient Educ Couns. 2018, 101:1865-70. 10.1016\/j.pec.2018.06.004","journal-title":"Patient Educ Couns"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2196\/24302","article-title":"Educational needs and preferences for Patient-Centered Outcomes Research in the cystic fibrosis community: mixed methods study","volume":"5","author":"Godfrey EM","year":"2021","unstructured":"Godfrey EM, Kazmerski TM, Brown G, Thayer EK, Mentch L, Pam M, Al Achkar M. Educational needs and preferences for Patient-Centered Outcomes Research in the cystic fibrosis community: mixed methods study. JMIR Form Res. 2021, 5:e24302. 10.2196\/24302","journal-title":"JMIR Form Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30337-6\u00a0","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell SC","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al.. The future of cystic fibrosis care: a global perspective. Lancet. 2020, 8:65-124. 10.1016\/S2213-2600(19)30337-6\u00a0","journal-title":"Lancet"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.7759","article-title":"Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of \u2018people like me\u2019","volume":"14","author":"Hutchings M","year":"2022","unstructured":"Hutchings M, Kirkpatrick S, Arden MA, et al.. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of \u2018people like me\u2019. Cureus. 2022, 14:26511-10. 10.7759","journal-title":"Cureus"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1177\/14799731211017895","article-title":"Physiotherapy service provision in a specialist adult cystic fibrosis service: a pre-post design study with the inclusion of an allied health assistant","volume":"18","author":"Hall K","year":"2021","unstructured":"Hall K, Maxwell L, Cobb R, et al.. Physiotherapy service provision in a specialist adult cystic fibrosis service: a pre-post design study with the inclusion of an allied health assistant. Chron Respir Dis. 2021, 18:10.1177\/14799731211017895","journal-title":"Chron Respir Dis"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0942-3","article-title":"A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial","volume":"19","author":"Cox NS","year":"2019","unstructured":"Cox NS, Eldridge B, Rawlings S, et al.. A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial. BMC Pulm Med. 2019, 19:253. 10.1186\/s12890-019-0942-3","journal-title":"BMC Pulm Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2019-0212\u00a0","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson KM","year":"2021","unstructured":"Dickinson KM, Collaco JM. Cystic fibrosis. Pediatr Rev. 2021, 42:55-67. 10.1542\/pir.2019-0212\u00a0","journal-title":"Pediatr Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178564-hope-in-every-breath-navigating-the-therapeutic-landscape-of-cystic-fibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:40Z","timestamp":1707509020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178564-hope-in-every-breath-navigating-the-therapeutic-landscape-of-cystic-fibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":78,"URL":"https:\/\/doi.org\/10.7759\/cureus.43603","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,16]]}}}